Covalent drugs are experiencing renewed interest in pharmaceutical development, with an increasing number of approvals over the past decade spanning multiple therapeutic conditions. This drug class, which forms permanent chemical bonds with target proteins, represents a continuation of a therapeutic approach that began with aspirin's approval in 1899.
The mechanism of covalent drugs involves forming irreversible bonds with their molecular targets, creating unique pharmacokinetic properties that distinguish them from traditional reversible inhibitors. Penicillin, approved shortly after aspirin, exemplifies the transformative potential of this drug class and remains one of the most significant pharmaceutical breakthroughs in medical history.